DNMT3A and acute myeloid leukemia: Two of the predicted drug combinations include procaine, a known inhibitor of the DNA methyltransferase enzymes DNMT1 and DNMT3A, which catalyze DNA methylation, and their activation has oncogenic roles in AML [71].